New Disease-Modifying Therapy Brings Good News for Early-Stage Alzheimer’s Patients

Early-stage Alzheimer’s patients have another choice in slowing their disease today, with U.S. Food and Drug Administration (FDA) approval of donanemab. UsAgainstAlzheimer’s celebrates this new choice for patients.

UsAgainstAlzheimer’s Board Member Wins Emmy for Alzheimer’s Documentary

UsAgainstAlzheimer’s chair and co-founder, George Vradenburg, released the following statement in response to board member Greg O’Brien’s recent Emmy win for the documentary, Have You Heard About Greg.

Join the UsAgainstAlzheimer's Membership Program

Become a Member of UsAgainstAlzheimer's today and join a movement of people who don’t just talk about the Alzheimer’s crisis, but become part of the solution.

More Evidence that “What’s Good for the Heart is Even Better for The Brain” in early-stage Alzheimer’s patients

New study demonstrates how diet, exercise, and other interventions improved brain cognition and function after just 20 weeks

2024 Brain Health Academy

UsAgainstAlzheimer’s is bringing back its Brain Health Academy in May 2024. First launched in 2022, the Academy offers a free, comprehensive virtual program designed to equip healthcare providers and wellness professionals with the necessary tools and resources to reduce the risks associated with Alzheimer’s and related dementias. In collaboration with the American Society on Aging, participants will receive free continuing education credits to enhance their professional development and growth. Learn more about how you can access this resource today.

Listen to the BrainStorm Podcast

Featuring conversations with healthcare providers, researchers, authors, experts, caregivers, and more, BrainStorm is breaking through the silence of Alzheimer's disease. Tune in on the first and third Tuesdays of every month for a new episode, with our host, Meryl Comer.

Good News for Early-Stage Alzheimer’s Patients

Alzheimer’s Documentary Wins Emmy

Become a Member

"What’s Good for the Heart is Even Better for The Brain”

2024 Brain Health Academy

Listen to the BrainStorm Podcast

UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and access to treatments – all regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.


Alzheimer’s is not a normal part of aging. There are things we can all do to reduce our risk, like eating a healthy diet, exercising, and getting good sleep. People need to know what’s good for the body is good for the brain. Learn more about our prevention work and how you can take charge of your brain health.


Early Detection & Diagnosis

Early detection and diagnosis give people a better chance of managing the disease. On top of that, current treatments are most effective with patients in the early stages of dementia.

Find out how we are raising awareness of the importance of early detection and how BrainGuide is helping people concerned about their brain health start a conversation with their doctor.


Access to Treatments

We are working on multiple fronts to get safe and effective treatments into the hands of people who need them most. That includes working to ensure Alzheimer’s patients are treated fairly as the federal government considers drug approval and Medicare coverage for treatments.

See how else UsAgainstAlzheimer’s is fighting for access to treatments.



Center for Brain Health Equity

Most Alzheimer’s patients are women, Latinos, and Black people. As a patient-centered organization, all our work is done with equity in mind, so we are addressing needs of the people who are most heavily impacted by the disease. Learn more about how UsAgainstAlzheimer’s Center for Brain Health Equity is working toward a healthcare system that works for everyone.

Recent News and Blog Posts

  • October 05, 2022

    New Bipartisan Bill would Prevent CMS from Denying Coverage for Entire Classes of Drugs

    Following the unconscionable and historic decision by the Centers for Medicare and...

    Read more
  • September 28, 2022

    Lecanemab’s Positive Clinical Trial Results Give Alzheimer’s Patients Hope

    Alzheimer’s patients and their loved ones have new reason for hope following...

    Read more
  • September 27, 2022

    Months After Denying Medicare Coverage for Alzheimer’s Drugs, CMS Announces a Premium Cut

    The Centers for Medicare and Medicaid Services (CMS) has announced it plans...

    Read more
  • Letter from Leading Alz Researchers: Journal “overstates and distorts” influence of flawed 2016 study

    In a letter to the editor published in Science responding to the...

    Read more
  • August 08, 2022

    FDA Deals Major Blow to Patients with Alzheimer’s-Related Psychosis

    Yesterday, Acadia Pharmaceuticals announced that it has been told by the FDA...

    Read more
  • A-LIST Pulse of the Community Vol 12, August 2022

    The mission of the A-LIST is to leverage data to make life...

    Read more


  • Resources

    2022 Annual Report

  • Resources
    alist 2023

    A-LIST Pulse of the Community – July 2023

  • Resources

    A-LIST Pulse of the Community – November 2022